Advertisement
Organisation › Details
Forbion (Group)
Forbion is a dedicated life sciences venture capital firm with offices in The Netherlands, Germany and Boston. Forbion invests in life sciences companies that are active in the (bio-) pharmaceutical space. Forbion manages €3 billion across multiple fund strategies that cover all stages of (bio-) pharmaceutical drug development. Forbion’s current team consists of over 30 life sciences investment professionals that have built an impressive performance track record since the late nineties with investments in over 95 companies across 8 funds. Forbion’s record of sourcing, building and guiding life sciences companies has resulted in many breakthrough therapies and valuable exits. Recent portfolio company successes include Inversago, Vectiv Bio, Versanis, Gyroscope, NewAmsterdam Pharma (NASDAQ: NAMS), Engene (NASDAQ: ENGN), and Replimune (NASDAQ: REPL). Besides financial objectives, Forbion selects investments that will positively affect the health and well-being of patients. The firm is a signatory to the United Nations Principles for Responsible Investment. Forbion operates a joint venture with BGV, the manager of seed and early-stage funds, especially focused on Benelux and Germany. *
Start | 2006-12-01 splitoff | |
Today | Forbion Capital Partners (NL) | |
Predecessor | ABN AMRO Capital Life Sciences | |
Industry | venture capital | |
Industry 2 | LIFE SCIENCES | |
Person | Slootweg, Sander (Forbion Capital Partners 20111 Managing Partner before ABN AMRO Capital) | |
Person 2 | Kersten, Dirk (Forbion 201810– General Partner before Inkef Capital + Gilde Healthcare) | |
Region | Naarden | |
Country | Netherlands | |
Street | 2-35 Gooimeer | |
City | 1411 DC Naarden | |
Tel | +31-35-699-3000 | |
Address record changed: 2021-04-24 | ||
Basic data | Employees | B: 11 to 50 (2024-01-09) |
Currency | EUR | |
Annual sales | 3,000,000,000 (capital under management (2024) 2024-01-09) | |
* Document for »About Section«: Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion". | ||
Record changed: 2024-03-23 |
Advertisement
More documents for Forbion (Group)
- [1] Engrail Therapeutics, Inc.. (3/19/24). "Press Release: Engrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies". San Diego, CA....
- [2] Forbion Capital Partners. (1/9/24). "Press Release: Forbion Portfolio Company Aiolos Bio, Inc. (Aiolos) to Be Acquired by GSK for up to $1.4 Billion"....
- [3] Kynexis B.V.. (11/7/23). "Press Release: Kynexis Launched to Advance Precision Therapeutics for Brain Diseases". Naarden....
- [4] F2G Ltd.. (8/4/22). "Press Release: F2G Announces $70 Million Financing to Advance Development and Commercialization of New Antifungal Agent Olorofim". Manchester....
- [5] Gyroscope Therapeutics Ltd.. (3/26/21). "Press Release: Gyroscope Therapeutics Announces $148 Million Raised in Series C Financing". London....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top